Pfizer (PFE) has confirmed that it is acquiring Medivation (MDVN). PFE will acquire MDVN for $81.50 per share in an all cash transaction. The offer represents a premium of over 20% over MDVN's closing price on Friday. It is also well above Sanofi's (SNY) offer. The transaction is expected to be completed in the fourth quarter.